Junshi Biosciences Wins NMPA Nod to Expand Toripalimab Use in Early-Stage Lung Cancer
I'm LongbridgeAI, I can summarize articles.Shanghai Junshi Biosciences received NMPA acceptance to expand toripalimab's indication for resectable stage II–III non-small cell lung cancer. The approval, backed by the phase III NEOTORCH trial showing significant event-free survival improvement, broadens the label from stage IIIA–IIIB. This move strengthens Junshi's immuno-oncology portfolio in China's competitive market.
An announcement from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.
Shanghai Junshi Biosciences has received acceptance from China’s National Medical Products Administration for a supplemental application to expand the approved indication of its PD-1 inhibitor toripalimab (TUOYI). The revision seeks to use toripalimab plus platinum-based chemotherapy as perioperative treatment, followed by toripalimab monotherapy as adjuvant therapy, in adult patients with resectable stage II–III non-small cell lung cancer, broadening the current label from stage IIIA–IIIB.
The application is backed by the phase III NEOTORCH trial in 501 resectable stage II–III NSCLC patients, which showed toripalimab plus chemotherapy significantly improved event-free survival versus chemotherapy alone, cut the risk of recurrence or death by about 60%, and dramatically boosted major pathological and complete remission rates. Acceptance of this expanded indication underscores toripalimab’s potential to reshape perioperative NSCLC care in China, strengthening Junshi’s immuno-oncology portfolio and offering more effective treatment options for a high-burden cancer with historically limited benefits from chemotherapy alone.
The most recent analyst rating on (HK:1877) stock is a Hold
with a HK$34.70 price target.
To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock,
see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company focused on developing and manufacturing innovative oncology therapies. Its core products include toripalimab (TUOYI), a domestically developed anti-PD-1 monoclonal antibody targeting solid tumors, with a growing presence in perioperative and adjuvant treatment settings for non-small cell lung cancer in the Chinese market.
The company operates in the highly competitive immuno-oncology segment, where PD-1/PD-L1 inhibitors have become standard of care for multiple cancer indications. By advancing toripalimab across broader stages of resectable NSCLC, Junshi is positioning itself as a key domestic player in China’s rapidly expanding market for immune checkpoint inhibitors, aiming to capture demand in earlier-stage, surgically resectable disease.
Average Trading Volume: 4,037,328
Technical Sentiment Signal: Sell
Current Market Cap: HK$35.64B
For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.